Patents by Inventor Yong Liang Zhu

Yong Liang Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11865120
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: January 9, 2024
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20230043970
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 9, 2023
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20220354864
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: February 25, 2022
    Publication date: November 10, 2022
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20220251049
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: August 11, 2022
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11304957
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: April 19, 2022
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 11208388
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: December 28, 2021
    Assignee: NEUPHARMA, INC
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20210353602
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 18, 2021
    Inventors: Guoxian Wu, Jiazhong Zhang, Yong-Liang Zhu, Chao Zhang, Prabha N. Ibrahim, Songyuan Shi, Wayne Spevak, Dean R. Artis, James Tsai
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20210346358
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 11, 2021
    Inventors: Guoxian Wu, Jiazhong Zhang, Yong-Liang Zhu, Chao Zhang, Prabha N. Ibrahim, Songyuan Shi, Wayne Spevak, Dean R. Artis, James Tsai
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210163423
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Certain chemical entities, compositions, and methods
    Patent number: 10947201
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 16, 2021
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210040048
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 11, 2021
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER
    Publication number: 20200390763
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20200306259
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 1, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Certain chemical entities, compositions, and methods
    Patent number: 10759766
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: September 1, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200172495
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 4, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 10653701
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 19, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10590106
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 17, 2020
    Assignee: NeuPharma, Inc.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200055828
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 20, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
    Patent number: 10561652
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 18, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10544106
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 28, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu